Ultrasound echogenicity reveals the response of breast cancer to chemotherapy.

PURPOSE To evaluate the ultrasound (US) response in patients with breast cancer (BC) during neoadjuvant chemotherapy (NAC). METHODS Prospective US analysis was performed on 19 malignant tumors prior to NAC treatment and 7 days after each first four courses of NAC in 13 patients (median age = 57 years). Echogenicity, size, vascularity, and sonoelastography were measured and compared with posttreatment scores of residual cancers burden. RESULTS Changes in the echogenicity of tumors after 3 courses of NAC had the most statistically strong correlation with the percentage of residual malignant cells used in histopathology to assess the response to treatment (odds ratio = 60, p < 0.05). Changes in lesion size and elasticity were also significant (p < 0.05). CONCLUSIONS There is a statistically significant relationship between breast tumors' echogenicity in US, neoplasm size, and stiffness and the response to NAC. In particular, our results show that the change in tumor echogenicity could predict a pathological response with satisfactory accuracy and may be considered in NAC monitoring.

[1]  Les Irwig,et al.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. , 2013, Journal of the National Cancer Institute.

[2]  Gregory J. Czarnota,et al.  Non-invasive evaluation of breast cancer response to chemotherapy using quantitative ultrasonic backscatter parameters , 2015, Medical Image Anal..

[3]  M. Lobbes,et al.  Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge , 2012 .

[4]  H. Tsunoda,et al.  Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy , 2017, Breast Cancer.

[5]  C. Purdie,et al.  Identification of pathological complete response after neoadjuvant chemotherapy for breast cancer: comparison of greyscale ultrasound, shear wave elastography, and MRI. , 2018, Clinical radiology.

[6]  Shuo Zhang,et al.  Comparison of strain and shear-wave ultrasounic elastography in predicting the pathological response to neoadjuvant chemotherapy in breast cancers , 2017, European Radiology.

[7]  Michael C. Kolios,et al.  Low-frequency quantitative ultrasound imaging of cell death in vivo. , 2013, Medical Physics (Lancaster).

[8]  Yan‐Lin Gu,et al.  Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta‐analysis , 2017, Clinical breast cancer.

[9]  F. Fuller-Pace,et al.  Prediction of pathological complete response to neoadjuvant chemotherapy for primary breast cancer comparing interim ultrasound, Shear Wave elastography and MRI , 2018, Senologie - Zeitschrift für Mammadiagnostik und -therapie.

[10]  Standards of the Polish Ultrasound Society – update. Sonomammography examination , 2012, Journal of ultrasonography.

[11]  Consuelo Morigi,et al.  Highlights from the 15th St Gallen International Breast Cancer Conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer , 2017, Ecancermedicalscience.

[12]  Hsiang-Yang Ma,et al.  Window-modulated compounding Nakagami imaging for ultrasound tissue characterization. , 2014, Ultrasonics.

[13]  F. Fuller-Pace,et al.  Prädiktion der pathologischen Komplettremission nach neoadjuvanter Chemotherapie bei primärem Mammakarzinom mittels Interim Ultraschall, Shearwave-Elastografie und MRT , 2017 .

[14]  Michael C. Kolios,et al.  Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy , 2013, Clinical Cancer Research.

[15]  W. Tran,et al.  Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using quantitative ultrasound, texture, and molecular features , 2018, PloS one.

[16]  Z. Varga,et al.  Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. , 2018, Breast.

[17]  Gregory J. Czarnota,et al.  Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach , 2016, Oncotarget.

[18]  Vandana Dialani,et al.  Role of Imaging in Neoadjuvant Therapy for Breast Cancer , 2015, Annals of Surgical Oncology.

[19]  T P O'Neill,et al.  Breast ultrasound. , 1998, The Surgical clinics of North America.

[20]  J. V. van Engelshoven,et al.  Preoperative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. , 2003, European journal of radiology.

[21]  A. Tutt,et al.  Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer , 2012, Annals of Surgical Oncology.

[22]  M. Oelze,et al.  Improved parameter estimates based on the homodyned K distribution , 2009, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[23]  Michael C. Kolios,et al.  Ultrasound imaging of apoptosis in tumor response: novel preclinical monitoring of photodynamic therapy effects. , 2008, Cancer research.

[24]  S. Giordano,et al.  Update on locally advanced breast cancer. , 2003, The oncologist.

[25]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[26]  Tsuyoshi Shiina,et al.  WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2: breast. , 2015, Ultrasound in medicine & biology.

[27]  Mehrdad J. Gangeh,et al.  Quantitative evaluation of cell death response in vitro and in vivo using conventional-frequency ultrasound , 2015, Oncoscience.

[28]  Gregory J. Czarnota,et al.  Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities , 2017, Scientific Reports.

[29]  A. Thompson,et al.  Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? , 2013, British Journal of Cancer.

[30]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.